PMID- 28341733
OWN - NLM
STAT- MEDLINE
DCOM- 20180326
LR  - 20220330
IS  - 1592-8721 (Electronic)
IS  - 0390-6078 (Print)
IS  - 0390-6078 (Linking)
VI  - 102
IP  - 7
DP  - 2017 Jul
TI  - Effect of antithymocyte globulin source on outcomes of bone marrow 
      transplantation for severe aplastic anemia.
PG  - 1291-1298
LID - 10.3324/haematol.2017.164459 [doi]
AB  - For treatment of severe aplastic anemia, immunosuppressive therapy with horse 
      antithymocyte globulin results in superior response and survival compared with 
      rabbit antithymocyte globulin. This relative benefit may be different in the 
      setting of transplantation as rabbit antithymocyte globulin results in more 
      profound immunosuppression. We analyzed 833 severe aplastic anemia transplants 
      between 2008 and 2013 using human leukocyte antigen (HLA)-matched siblings 
      (n=546) or unrelated donors (n=287) who received antithymocyte globulin as part 
      of their conditioning regimen and bone marrow graft. There were no differences in 
      hematopoietic recovery by type of antithymocyte globulin. Among recipients of 
      HLA-matched sibling transplants, day 100 incidence of acute (17% versus 6%, 
      P<0.001) and chronic (20% versus 9%, P<0.001) graft-versus-host disease were 
      higher with horse compared to rabbit antithymocyte globulin. There were no 
      differences in 3-year overall survival, 87% and 92%, P=0.76, respectively. Among 
      recipients of unrelated donor transplants, acute graft-versus-host disease was 
      also higher with horse compared to rabbit antithymocyte globulin (42% versus 23%, 
      P<0.001) but not chronic graft-versus-host disease (38% versus 32%, P=0.35). 
      Survival was lower with horse antithymocyte globulin after unrelated donor 
      transplantation, 75% versus 83%, P=0.02. These data support the use of rabbit 
      antithymocyte globulin for bone marrow transplant conditioning for severe 
      aplastic anemia.
CI  - Copyright(c) 2017 Ferrata Storti Foundation.
FAU - Kekre, Natasha
AU  - Kekre N
AD  - Division of Hematology, The Ottawa Hospital, ON, Canada.
FAU - Zhang, Ying
AU  - Zhang Y
AD  - Division of Biostatistics, Institute for Health and Society, Medical College of 
      Wisconsin, Milwaukee, WI, USA.
FAU - Zhang, Mei-Jie
AU  - Zhang MJ
AD  - Division of Biostatistics, Institute for Health and Society, Medical College of 
      Wisconsin, Milwaukee, WI, USA.
AD  - Center for International Blood and Marrow Transplant Research, Department of 
      Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
FAU - Carreras, Jeanette
AU  - Carreras J
AD  - Center for International Blood and Marrow Transplant Research, Department of 
      Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
FAU - Ahmed, Parvez
AU  - Ahmed P
AD  - Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan.
FAU - Anderlini, Paolo
AU  - Anderlini P
AD  - Department of Stem Cell Transplantation and Cellular Therapy, The University of 
      Texas MD Anderson Cancer Center, Houston, TX, USA.
FAU - Atta, Elias Hallack
AU  - Atta EH
AD  - Instituto Nacional de Cancer, Rio de Janeiro, Brazil.
FAU - Ayas, Mouhab
AU  - Ayas M
AD  - Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital & 
      Research Center, Riyadh, Saudi Arabia.
FAU - Boelens, Jaap Jan
AU  - Boelens JJ
AD  - Department of Pediatrics, University Medical Center Utrecht, The Netherlands.
FAU - Bonfim, Carmem
AU  - Bonfim C
AD  - Hospital de Clinicas, Federal University of Parana, Curitiba, Brazil.
FAU - Deeg, H Joachim
AU  - Deeg HJ
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 
      USA.
FAU - Kapoor, Neena
AU  - Kapoor N
AD  - Division of Hematology, Oncology and Blood & Marrow Transplantation, Children's 
      Hospital Los Angeles, CA, USA.
FAU - Lee, Jong-Wook
AU  - Lee JW
AD  - BMT Center, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, 
      South Korea.
FAU - Nakamura, Ryotaro
AU  - Nakamura R
AD  - Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, 
      Duarte, CA, USA.
FAU - Pulsipher, Michael A
AU  - Pulsipher MA
AD  - Division of Hematology, Oncology and Blood & Marrow Transplantation, Children's 
      Hospital Los Angeles, CA, USA.
FAU - Eapen, Mary
AU  - Eapen M
AD  - Center for International Blood and Marrow Transplant Research, Department of 
      Medicine, Medical College of Wisconsin, Milwaukee, WI, USA meapen@mcw.edu.
FAU - Antin, Joseph H
AU  - Antin JH
AD  - Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, 
      USA.
LA  - eng
GR  - U24 CA076518/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20170324
PL  - Italy
TA  - Haematologica
JT  - Haematologica
JID - 0417435
RN  - 0 (Antilymphocyte Serum)
SB  - IM
CIN - Haematologica. 2017 Jul;102(7):1137-1138. PMID: 28655810
MH  - Adolescent
MH  - Adult
MH  - Anemia, Aplastic/diagnosis/mortality/*therapy
MH  - Antilymphocyte Serum/*therapeutic use
MH  - *Bone Marrow Transplantation/adverse effects/methods
MH  - Comorbidity
MH  - Female
MH  - Graft vs Host Disease/etiology
MH  - Histocompatibility Testing
MH  - Humans
MH  - Infections/etiology
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Siblings
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Unrelated Donors
MH  - Young Adult
PMC - PMC5566045
EDAT- 2017/03/28 06:00
MHDA- 2018/03/27 06:00
PMCR- 2017/07/01
CRDT- 2017/03/26 06:00
PHST- 2017/01/12 00:00 [received]
PHST- 2017/03/16 00:00 [accepted]
PHST- 2017/03/28 06:00 [pubmed]
PHST- 2018/03/27 06:00 [medline]
PHST- 2017/03/26 06:00 [entrez]
PHST- 2017/07/01 00:00 [pmc-release]
AID - haematol.2017.164459 [pii]
AID - 1021291 [pii]
AID - 10.3324/haematol.2017.164459 [doi]
PST - ppublish
SO  - Haematologica. 2017 Jul;102(7):1291-1298. doi: 10.3324/haematol.2017.164459. Epub 
      2017 Mar 24.